Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic
暂无分享,去创建一个
Ravi Iyengar | Darrell R. Abernethy | Paolo Vicini | Douglas A. Lauffenburger | Andrea Califano | James L. Stevens | Shankar Subramaniam | William J. Jusko | Brian Shoichet | Kim L. R. Brouwer | D. Lauffenburger | P. Sorger | R. Iyengar | B. Shoichet | A. Califano | W. Jusko | S. Subramaniam | K. Brouwer | P. Vicini | D. Abernethy | J. Stevens | R. Lalonde | Rebecca J Ward | Sandra R. B. Allerheiligen | S. Allerheiligen | P. D. Graaf | Russ B. Altman | Z. David | D'Argenio | Richard Lalonde | Piet Van der Graaf | Rebecca Ward | Z. David | D'argenio | P. H. Graaf | Piet H van der Graaf | Piet H. van der Graaf | D. Z. D 'argenio | Richard Lalonde | Wab | Richard L. Lalonde
[1] J. A. Hendricks,et al. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). , 2011, Journal of medicinal chemistry.
[2] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[3] Neil Benson,et al. Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.
[4] Andrew Johnston,et al. Genome-Wide Expression Profiling of Five Mouse Models Identifies Similarities and Differences with Human Psoriasis , 2011, PloS one.
[5] M. Duffy,et al. Use of molecular markers for predicting therapy response in cancer patients. , 2011, Cancer treatment reviews.
[6] Peter K. Sorger,et al. Measuring and Modeling Apoptosis in Single Cells , 2011, Cell.
[7] M. Joyner,et al. Physiology: alone at the bottom, alone at the top , 2011, The Journal of physiology.
[8] J. DiMasi,et al. Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 , 2011, Clinical pharmacology and therapeutics.
[9] Bin Hu,et al. Hierarchical graphs for rule-based modeling of biochemical systems , 2011, BMC Bioinformatics.
[10] M. Elowitz,et al. Functional roles for noise in genetic circuits , 2010, Nature.
[11] Marc Pfister,et al. Fostering Culture and Optimizing Organizational Structure for Implementing Model‐Based Drug Development , 2010, Journal of clinical pharmacology.
[12] William W. Chen,et al. Classic and contemporary approaches to modeling biochemical reactions. , 2010, Genes & development.
[13] G. Verheyen,et al. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.
[14] P Vicini,et al. Multiscale Modeling in Drug Discovery and Development: Future Opportunities and Present Challenges , 2010, Clinical pharmacology and therapeutics.
[15] R. Iyengar,et al. Training in Systems Pharmacology: Predoctoral Program in Pharmacology and Systems Biology at Mount Sinai School of Medicine , 2010, Clinical pharmacology and therapeutics.
[16] K. Burrage,et al. The Systems Biology Approach to Drug Development: Application to Toxicity Assessment of Cardiac Drugs , 2010, Clinical pharmacology and therapeutics.
[17] P. Sorger,et al. Dissecting Variability in Responses to Cancer Chemotherapy Through Systems Pharmacology , 2010, Clinical pharmacology and therapeutics.
[18] Mariano J. Alvarez,et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers , 2010, Molecular systems biology.
[19] G. Ramani,et al. Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension , 2010, Drug design, development and therapy.
[20] R. Iyengar,et al. Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.
[21] D. Lauffenburger,et al. Networks Inferred from Biochemical Data Reveal Profound Differences in Toll-like Receptor and Inflammatory Signaling between Normal and Transformed Hepatocytes* , 2010, Molecular & Cellular Proteomics.
[22] R. Weissleder,et al. Hybrid PET-optical imaging using targeted probes , 2010, Proceedings of the National Academy of Sciences.
[23] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[24] J. Uhm,et al. The transcriptional network for mesenchymal transformation of brain tumours , 2010 .
[25] Sabrina L Spencer,et al. Non-genetic Cell-to-cell Variability and the Consequences for Pharmacology This Review Comes from a Themed Issue on Omics Edited the Distribution of Protein Abundance and Resulting Variability in Phenotype Measuring Cell-to-cell Variation , 2022 .
[26] Johan Gabrielsson,et al. Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. , 2009, Future medicinal chemistry.
[27] Dorothy D. Sears,et al. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization , 2009, Proceedings of the National Academy of Sciences.
[28] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[29] Sarala M. Wimalaratne,et al. The Systems Biology Graphical Notation , 2009, Nature Biotechnology.
[30] Aviv Regev,et al. Transcriptional Regulatory Circuits: Predicting Numbers from Alphabets , 2009, Science.
[31] M. Boguski,et al. Repurposing with a Difference , 2009, Science.
[32] P. Sorger,et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.
[33] Janice M Reichert,et al. Development trends for therapeutic antibody fragments , 2009, Nature Biotechnology.
[34] Vincent Danos,et al. Internal coarse-graining of molecular systems , 2009, Proceedings of the National Academy of Sciences.
[35] B. Agoram,et al. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. , 2009, British journal of clinical pharmacology.
[36] Tanya Coleman,et al. In Silico and in Vitro Modeling of Hepatocyte Drug Transport Processes: Importance of ABCC2 Expression Levels in the Disposition of Carboxydichlorofluroscein , 2009, Drug Metabolism and Disposition.
[37] Ravi Iyengar,et al. Systems pharmacology and genome medicine: a future perspective , 2009, Genome Medicine.
[38] James R Faeder,et al. Rule-based modeling of biochemical systems with BioNetGen. , 2009, Methods in molecular biology.
[39] A. Ferrando,et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL , 2008, Nature Medicine.
[40] D. Lauffenburger,et al. Modeling a Snap-Action, Variable-Delay Switch Controlling Extrinsic Cell Death , 2008, PLoS biology.
[41] G. Augustine,et al. A Positive Feedback Signal Transduction Loop Determines Timing of Cerebellar Long-Term Depression , 2008, Neuron.
[42] Stephen S. Taylor,et al. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. , 2008, Cancer cell.
[43] DE Mager,et al. Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.
[44] Marc R Gastonguay,et al. Pharmacometrics: A Multidisciplinary Field to Facilitate Critical Thinking in Drug Development and Translational Research Settings , 2008, Journal of clinical pharmacology.
[45] K. Basso,et al. A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas , 2008, Molecular systems biology.
[46] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[47] P. Donnelly,et al. New models of collaboration in genome-wide association studies: the Genetic Association Information Network , 2007, Nature Genetics.
[48] R. Lalonde,et al. Introduction of Quantitative Methods in Pharmacology and Clinical Pharmacology: A Historical Overview , 2007, Clinical pharmacology and therapeutics.
[49] W Ewy,et al. Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.
[50] Rajesh Krishna,et al. Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[51] E. Butcher,et al. Can cell systems biology rescue drug discovery? , 2007, Ernst Schering Research Foundation workshop.
[52] D. Kell. Systems biology, metabolic modelling and metabolomics in drug discovery and development. , 2006, Drug discovery today.
[53] D. Lauffenburger,et al. Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.
[54] M. Meyerson,et al. Genomic Approaches to Lung Cancer , 2006, Clinical Cancer Research.
[55] Patrice Degoulet,et al. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance , 2006, Comput. Biol. Medicine.
[56] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[57] Timothy J Mitchison,et al. Small molecule screening by imaging. , 2006, Current opinion in chemical biology.
[58] Eric J Kunkel,et al. Systems biology in drug discovery. , 2006, Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.
[59] B. Corrigan,et al. How Modeling and Simulation Have Enhanced Decision Making in New Drug Development , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[60] Garry Jennings,et al. Finding improved medicines: the role of academic–industrial collaboration , 2005, Nature Reviews Drug Discovery.
[61] J. Collins,et al. Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks , 2005, Nature Biotechnology.
[62] Y. Lazebnik. Can a biologist fix a radio? — or, what I learned while studying apoptosis , 2004, Biochemistry (Moscow).
[63] W. Bialek,et al. Physical limits to biochemical signaling. , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[64] David E Hill,et al. Academia-industry collaboration: an integral element for building "omic" resources. , 2004, Genome research.
[65] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[66] J. Paulsson. Summing up the noise in gene networks , 2004, Nature.
[67] Hartmut Derendorf,et al. Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.
[68] D. L. Taylor,et al. Advances in high content screening for drug discovery. , 2003, Assay and drug development technologies.
[69] D. Noble. Modeling the Heart--from Genes to Cells to the Whole Organ , 2002, Science.
[70] E. Oren,et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.
[71] U. Bhalla,et al. Emergent properties of networks of biological signaling pathways. , 1999, Science.
[72] S. Shenolikar,et al. Gating of CaMKII by cAMP-regulated protein phosphatase activity during LTP. , 1998, Science.
[73] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[74] C. Grosvenor,et al. Role of dopamine in anterior pituitary tubulin pools in the lactating rat. , 1990, Neuroreport.
[75] H. Berg,et al. Physics of chemoreception. , 1977, Biophysical journal.
[76] J. Black,et al. Definition and Antagonism of Histamine H2-receptors , 1972, Nature.
[77] T. G. Coleman,et al. Circulation: overall regulation. , 1972, Annual review of physiology.
[78] A. M. Lands,et al. Differentiation of Receptor Systems activated by Sympathomimetic Amines , 1967, Nature.
[79] A. Hodgkin,et al. A quantitative description of membrane current and its application to conduction and excitation in nerve , 1952, The Journal of physiology.
[80] R. Ahlquist,et al. A study of the adrenotropic receptors. , 1948, The American journal of physiology.
[81] G. Beadle,et al. Genetic Control of Biochemical Reactions in Neurospora , 1941 .